| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kalaris Therapeu | Posoleucel | Viruses after high-risk allogeneic hematopoietic cell transplant (allo-HCT) | Phase 3 | Trial Discontinued | Intravenous | Immunosuppressant |
| Kalaris Therapeu | Viralym-M (ALVR105) | Virus-associated hemorrhagic cystitis (HC) | Phase 3 | Trial Discontinued | Intravenous | N/A |
| Kalaris Therapeu | Posoleucel (Viralym-M, ALVR105) | BK viremia | Phase 2 | Intravenous | N/A | |
| KalVista Pharmaceuticals Inc. | Sebetralstat - (KONFIDENT-S) | Hereditary angioedema (HAE) | Phase 3 | Data Released | Oral | Genetic Disorder |
| KalVista Pharmaceuticals Inc. | Sebetralstat - (KONFIDENT-S) | Hereditary angioedema (HAE) | Phase 3 | Data Released | Oral | Genetic Disorder |
| KalVista Pharmaceuticals Inc. | Sebetralstat - (KONFIDENT-KID) | Hereditary angioedema (HAE) | Phase 3 | Data Released | Oral | Genetic Disorder |
| KalVista Pharmaceuticals Inc. | Sebetralstat - (KONFIDENT-S) | Hereditary angioedema (HAE) | Phase 3 | Data Released | Oral | Genetic Disorder |
| KalVista Pharmaceuticals Inc. | KVD824 - (KOMPLETE) | Hereditary angioedema (HAE) | Phase 2 | Trial Completed | Oral | Genetic Disorder |